Every 10-Q that HeartSciences Inc. (HSCS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HSCS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCS filings page.
HeartSciences Inc. (HSCS) reported another loss-making quarter and a strained balance sheet while pursuing a transformative merger with Fortitude Mining HoldCo. For the quarter ended July 31, 2026, revenue was only $2,100 and the company recorded a net loss of $3.17 million, wider than the prior-year loss of $2.05 million. Cash and cash equivalents fell to just $29,906, and stockholders’ equity shifted to a deficit of $2.03 million, prompting Nasdaq to notify HSCS that it no longer meets the $2.5 million equity listing requirement. Management discloses “substantial doubt” about the company’s ability to continue as a going concern and is relying on additional capital raises, including an at-the-market program and a $1.0 million private placement to Fortitude’s parent, and on closing the proposed Merger, under which Fortitude holders are expected to own about 95% of the combined company.
HeartSciences Inc. reported another loss-making quarter for the period ended January 31, 2026, with a nine‑month net loss of $6.4 million and minimal revenue of $4,319. Operating expenses were driven by research and development and general and administrative costs, while interest expense added further pressure.
Cash and cash equivalents were $3.4 million against $7.6 million in total assets and $4.9 million in total liabilities, leaving stockholders’ equity at $2.7 million. The company discloses substantial doubt about its ability to continue as a going concern and is relying on external financing, including a $3.6 million Streeterville note and a Series D preferred stock offering that raised about $6.7 million.
HeartSciences Inc. reported another loss-making quarter for the three months ended October 31, 2025 as it continues developing its AI‑driven ECG technologies. Revenue was $2,419 for the quarter and $4,319 for the six-month period, while net loss was $2,350,769 for the quarter and $4,405,763 year-to-date.
The company ended the period with $1,951,103 in cash and cash equivalents and total assets of $5,996,117. It reported an accumulated deficit of $80,533,398 and disclosed that these factors raise substantial doubt about its ability to continue as a going concern.
To fund operations, HeartSciences issued 1,912,383 Units of Series D convertible preferred stock and warrants at $3.50 per Unit for gross proceeds of approximately $6.7 million, with 1,332,544 Series D shares already converted into Common Stock. It also exchanged $2,020,000 of principal and interest on a Streeterville note into 570,626 Common shares and repaid an additional $450,000 in cash, fully retiring that note. Stockholders’ equity increased to $4,182,470 from $205,171 as of April 30, 2025, but management states current resources are insufficient to fund operations to achieve commercialization and plans to seek additional capital.